Detail akcie ANI Pharmaceuticals online

Business Summary: ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, ANI Pharmaceuticals Inc revenues increased 50% to $636.3M. Net income applicable to common stockholders totaled $44.8M vs. loss of $9.5M. Revenues reflect Rare Disease segment increase from $105.6M to $340.4M, Generics Established Brands and Other segment increase of 64% to $295.9M. Net Income reflects Contingent consideration fair value adju decrease from $1.3M (expense) to $25.3M (income).